On August 2nd 2023, BLUEPRINT MEDICINES ($NASDAQ:BPMC) announced their second quarter FY2023 earnings results for the period ending on June 30th 2023. The total revenue for the quarter was USD 57.6 million, showing a 57.5% increase compared to the same quarter of the previous year. Net income for the quarter improved from -159.7 million the previous year to -132.8 million.
The company’s stock opened at $59.3 and closed the day at $54.3, marking a plunge of 15.3% from its previous closing price of 64.1. The primary reason behind this decrease is believed to be the company’s inability to meet its projected targets for its drugs and treatments. BLUEPRINT MEDICINES is currently working on expanding its portfolio of products to make up for the lack of success in its existing ones. The company is also looking to optimize its cost structure and reduce expenses in order to improve its bottom line. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Blueprint Medicines. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Blueprint Medicines. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Blueprint Medicines. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Blueprint Medicines are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
We at GoodWhale recently performed an analysis of BLUEPRINT MEDICINES‘s wellbeing. Our Star Chart shows that BLUEPRINT MEDICINES is strong in asset, profitability, and medium in growth, but weak in dividend. Upon further research, we found that BLUEPRINT MEDICINES has a low health score of 3/10 considering its cashflows and debt, making it less likely to pay off debt and fund future operations. Our findings classify BLUEPRINT MEDICINES as an ‘elephant’, a type of company we conclude is rich in assets after deducting off liabilities. Companies such as BLUEPRINT MEDICINES are particularly appealing to long-term investors looking for companies which are more likely to remain stable financially and can potentially yield long-term returns. Thus, such investors may be interested in BLUEPRINT MEDICINES. More…
Risk Rating Analysis
Star Chart Analysis
Its main competitors are Theseus Pharmaceuticals Inc, Pardes Biosciences Inc, and Resverlogix Corp.
– Theseus Pharmaceuticals Inc ($NASDAQ:THRX)
With a market cap of 208.28M as of 2022, a return on equity of 21.98%, and a focus on developing treatments for cancer and other diseases, Theseus Pharmaceuticals Inc is a company to watch. While still relatively small, Thiseus has shown impressive growth and profitability, making it a company to keep an eye on in the coming years.
– Pardes Biosciences Inc ($NASDAQ:PRDS)
Pardes Biosciences Inc is a clinical stage biopharmaceutical company that focuses on developing drugs for the treatment of cancer and other diseases. The company’s market cap is 71.05M as of 2022. The company’s products are in various stages of development, including two Phase III clinical trials for the treatment of pancreatic cancer.
– Resverlogix Corp ($TSX:RVX)
Resverlogix Corp. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases. The company’s lead drug is RVX-208, a small molecule that is in Phase III clinical trials for the treatment of patients with apoA-I deficiency and high cardiovascular risk. Resverlogix Corp. was founded in 2000 and is headquartered in Calgary, Canada.
Blueprint Medicines reported their second quarter FY2023 earnings on August 2 2023, showing an impressive 57.5% year-over-year increase in total revenue. However, net income showed a less positive result, with a figure of -132.8 million, though still an improvement from the previous year’s figure of -159.7 million. Overall, investors should consider this mixed performance when making investment decisions in Blueprint Medicines, and could use further analysis and research to determine if current stock prices represent a buying opportunity with potential for future growth.